145 related articles for article (PubMed ID: 38334320)
1. Treatment patterns of galcanezumab versus standard of care preventive migraine medications over 24 months: a US retrospective claims study.
Varnado OJ; Vu M; Buysman EK; Kim G; Allenback G; Hoyt M; Trenz H; Cao F; Viktrup L
Curr Med Res Opin; 2024 Apr; 40(4):635-646. PubMed ID: 38334320
[TBL] [Abstract][Full Text] [Related]
2. Treatment Patterns for Calcitonin Gene-Related Peptide Monoclonal Antibodies Including Galcanezumab versus Conventional Preventive Treatments for Migraine: A Retrospective US Claims Study.
Varnado OJ; Manjelievskaia J; Ye W; Perry A; Schuh K; Wenzel R
Patient Prefer Adherence; 2022; 16():821-839. PubMed ID: 35378732
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Treatment Patterns in Patients with Migraine Initiating Calcitonin Gene-Related Peptide Monoclonal Antibodies: A Retrospective Real-World US Study.
Varnado OJ; Brady BL; Zagar AJ; Robles YP; Hoyt M
Patient Prefer Adherence; 2024; 18():69-88. PubMed ID: 38223442
[TBL] [Abstract][Full Text] [Related]
4. Health care resource utilization and costs associated with treatment among patients initiating calcitonin gene-related peptide inhibitors vs other preventive migraine treatments in the United States.
Varnado OJ; Manjelievskaia J; Ye W; Perry A; Schuh K; Wenzel R
J Manag Care Spec Pharm; 2022 Aug; 28(8):818-829. PubMed ID: 35876297
[No Abstract] [Full Text] [Related]
5. Persistence to anti-CGRP monoclonal antibodies and onabotulinumtoxinA among patients with migraine: a retrospective cohort study.
Charleston L; Talon B; Sullivan C; Anderson C; Kymes S; Regnier SA; Soni-Brahmbhatt S; Nahas SJ
J Headache Pain; 2023 Aug; 24(1):101. PubMed ID: 37532991
[TBL] [Abstract][Full Text] [Related]
6. Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies.
Schwedt TJ; Lee J; Knievel K; McVige J; Wang W; Wu Z; Gillard P; Shah D; Blumenfeld AM
J Manag Care Spec Pharm; 2023 Oct; 29(10):1119-1128. PubMed ID: 37776119
[No Abstract] [Full Text] [Related]
7. Treatment patterns for patients initiating novel acute migraine specific medications (nAMSMs) in the context of monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway.
Zhou Z; Urman R; Gill K; Park AS; Vuvu F; Patel LB; Lu J; Wade RL; Frerichs L; Bensink ME
J Headache Pain; 2023 Nov; 24(1):153. PubMed ID: 37946113
[TBL] [Abstract][Full Text] [Related]
8. Understanding the migraine treatment landscape prior to the introduction of calcitonin gene-related peptide inhibitors: Results from the Assessment of TolerabiliTy and Effectiveness in MigrAINe Patients using Preventive Treatment (ATTAIN) study.
Kawata AK; Shah N; Poon JL; Shaffer S; Sapra S; Wilcox TK; Shah S; Tepper SJ; Dodick DW; Lipton RB
Headache; 2021 Mar; 61(3):438-454. PubMed ID: 33594686
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of erenumab and onabotulinumtoxinA on acute medication usage and health care resource utilization as migraine prevention in the United States.
Tepper SJ; Fang J; Zhou L; Shen Y; Vo P; Abdrabboh A; Glassberg MB; Ferraris M
J Manag Care Spec Pharm; 2021 Sep; 27(9):1157-1170. PubMed ID: 33998825
[No Abstract] [Full Text] [Related]
10. Characteristics associated with response to subcutaneously administered anti-CGRP monoclonal antibody medications in a real-world community cohort of persons living with migraine: A retrospective clinical and genetic study.
Chase BA; Semenov I; Rubin S; Meyers S; Mark A; Makhlouf T; Chirayil TT; Maraganore D; Wei J; Zheng SL; Xu J; Epshteyn A; Pham A; Frigerio R; Markopoulou K
Headache; 2024 Jan; 64(1):68-92. PubMed ID: 38071464
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Galcanezumab for the Preventive Treatment of Migraine: A Narrative Review.
Martin V; Samaan KH; Aurora S; Pearlman EM; Zhou C; Li X; Pallay R
Adv Ther; 2020 May; 37(5):2034-2049. PubMed ID: 32319039
[TBL] [Abstract][Full Text] [Related]
12. A real-world study of acute and preventive medication use, adherence, and persistence in patients prescribed fremanezumab in the United States.
Krasenbaum LJ; Pedarla VL; Thompson SF; Tangirala K; Cohen JM; Driessen MT
J Headache Pain; 2022 May; 23(1):54. PubMed ID: 35508970
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial.
Mulleners WM; Kim BK; Láinez MJA; Lanteri-Minet M; Pozo-Rosich P; Wang S; Tockhorn-Heidenreich A; Aurora SK; Nichols RM; Yunes-Medina L; Detke HC
Lancet Neurol; 2020 Oct; 19(10):814-825. PubMed ID: 32949542
[TBL] [Abstract][Full Text] [Related]
14. Positive response to galcanezumab following treatment failure to onabotulinumtoxinA in patients with migraine: post hoc analyses of three randomized double-blind studies.
Ailani J; Pearlman E; Zhang Q; Nagy AJ; Schuh K; Aurora SK
Eur J Neurol; 2020 Mar; 27(3):542-549. PubMed ID: 31595600
[TBL] [Abstract][Full Text] [Related]
15. Patterns of anti-CGRP mAbs use and variation of triptan consumption following treatment initiation: A descriptive drug utilization study in the Tuscany region, Italy.
Hyeraci G; Paoletti O; Iannone LF; Gini R; De Cesaris F; Geppetti P; Roberto G
Headache; 2023; 63(10):1391-1402. PubMed ID: 37830925
[TBL] [Abstract][Full Text] [Related]
16. Patient characteristics and treatment utilization among patients with migraine initiating self-injectable calcitonin gene-related peptide monoclonal antibody and novel acute medication.
Varnado OJ; Hoyt M; Ye W; Nicholson R
Curr Med Res Opin; 2022 Aug; 38(8):1451-1457. PubMed ID: 35762152
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of galcanezumab in patients with migraine who did not benefit from commonly prescribed preventive treatments.
Kuruppu DK; Tobin J; Dong Y; Aurora SK; Yunes-Medina L; Green AL
BMC Neurol; 2021 Apr; 21(1):175. PubMed ID: 33892641
[TBL] [Abstract][Full Text] [Related]
18. Early onset of effect following galcanezumab treatment in patients with previous preventive medication failures.
Schwedt TJ; Kuruppu DK; Dong Y; Standley K; Yunes-Medina L; Pearlman E
J Headache Pain; 2021 Mar; 22(1):15. PubMed ID: 33765912
[TBL] [Abstract][Full Text] [Related]
19. Erenumab patient characteristics, medication adherence, and treatment patterns in the United States.
Hines DM; Shah S; Multani JK; Wade RL; Buse DC; Bensink M
Headache; 2021 Apr; 61(4):590-602. PubMed ID: 33594672
[TBL] [Abstract][Full Text] [Related]
20. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
Berman G; Croop R; Kudrow D; Halverson P; Lovegren M; Thiry AC; Conway CM; Coric V; Lipton RB
Headache; 2020 Sep; 60(8):1734-1742. PubMed ID: 32799325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
